Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

• Gilles Salles,
• Stephen J. Schuster,
• Sven de Vos,
• Nina D. Wagner-Johnston,
• Andreas Viardot,
• Kristie A. Blum,
• Christopher R. Flowers,
• Wojciech J. Jurczak,
• Ian W. Flinn,
• Brad S. Kahl,
• Peter Martin,
• Yeonhee Kim,
• Sanatan Shreay,
• Matthias Will,
• Bess Sorensen,
• Madlaina Breuleux,
• Pier Luigi Zinzani,
• Ajay K. Gopal

Affiliations

Gilles Salles

Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France

Stephen J. Schuster

Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA

Sven de Vos

Department of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Nina D. Wagner-Johnston

Departments of Oncology and Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA

Andreas Viardot

Department of Internal Medicine III, University Hospital of Ulm, Germany

Kristie A. Blum

Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA

Christopher R. Flowers

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA

Wojciech J. Jurczak

Department of Hematology, Jagiellonian University, Krakow, Poland

Ian W. Flinn

Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN, USA

Brad S. Kahl

Department of Medicine, Oncology Division, Washington University School of Medicine, St Louis, MO, USA

Peter Martin

Division of Hematology/Oncology, Weill Cornell Medical College, NY, USA

Yeonhee Kim

Gilead Sciences Inc., Foster City, CA, USA

Sanatan Shreay

Gilead Sciences Inc., Foster City, CA, USA

Matthias Will

At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA

Bess Sorensen

At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA

Madlaina Breuleux

At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA

Pier Luigi Zinzani

Institute of Hematology and Oncology, University of Bologna, Italy

Ajay K. Gopal

Medical Oncology Division, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA